Tensha: Epigenetic BET

Tensha developing bromodomain inhibitors for cancer, inflammation

Tensha Therapeutics Inc. believes its bromodomain inhibitors are among the first compounds to directly target the MYC oncogene.The company is focusing on cancer indications while eyeing additional opportunities in inflammatory disease.

Tensha was founded in July by HealthCare Ventures and funded with a $15 million series A round set to be announced this week. Douglas Onsi, a managing director of HealthCare Ventures and Tensha's president and CEO, believes the cash will be enough to bring a compound into Phase II testing in a cancer indication.

Bromodomain-containing

Read the full 830 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE